PHASE II TRIAL OF PHENYLACETIC ACID FOR RECURRENT MALIGNANT GILOMA SWOG9443

苯乙酸治疗复发性恶性胶质瘤的 II 期试验 SWOG9443

• 批准号: 6275817
• 负责人: MICHAEL BOZIK
• 金额: $ 1.91万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275817
• 关键词: clinical research; drug administration rate /duration; glioma; human subject; human therapy evaluation; intravenous administration; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; phenylacetates

This is a Phase II trial of phenylacetic acid for recurrent malignant glioma being conducted by the North American Brain Tumor consortitum (NABTC) and the Southwest Oncology Group (SWOG). It is anticipated that 10 patients will enter this study at the University of Pittsburgh Cancer Institute. Phenylacetate (PAA) will be given at a starting dose of 400 mg/kg/day (Ideal Body Weight) using a continous intravenous infusion, for 14 days, followed by a 14 day rest. A repeat 14 day infusion will be given, followed by a 14 day rest.

这是苯乙酸治疗复发性恶性肿瘤的II期临床试验 神经胶质瘤是由北美脑肿瘤协会进行的， （NABTC）和西南肿瘤组（SWOG）。 预计各国 10名患者将在匹兹堡大学癌症中心参加这项研究。 院 苯乙酸酯（PAA）将以400 mg/kg/天（理想体重），采用连续静脉输注， 14天，然后休息14天。 将重复14天输注 给予，然后休息14天。